Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of Parkinson’s disease (PD) consists of symptomatic treatments however neuroprotective strategies have remained elusive. Rasagiline (N-propargyl-1R-aminoindan) is a new, effective and selective monoamine oxidase-B inhibitor. Rasagiline was shown to have neuroprotective properties in various in vitro and in vivo models independently of MAO-B inhibition. Rasagiline inhibits MAO-B more effectively than selegiline and has the advantage of once daily dosing. However, in contrast to selegiline, rasagiline is not metabolized to amphetamine like products, which cause adverse side effects and neuronal cell death. Therefore, rasagiline, whose neuroprotective properties are basic by the production of neurotoxic metabolites, may have an advantage over selegiline in the treatment of Parkinson’s disease (PD). Rasagiline also show the Protective effect in Aminoglycoside Ototoxicity.